Purpose The aim of this study was to compare the measurements of diameter and volume of hepatic metastases from CT images with the overall survival and tumor response, in patients with unresectable liver metastases of colorectal cancer treated with a targeted agent.
INTRODUCTION
Liver metastases occur in 30% of all patients with colorectal cancer (CRC), and are responsible for death in at least two thirds of CRC patients. Approximately 80% of patients with colorectal liver metastasis (CLM) present with unresectable disease at initial diagnosis (1, 2) .
Profound improvements in CLM outcome seem to be associated with advancements in medical therapy, and the increased use of hepatic resection (3) . Additionally, a disease-free interval longer than 5 years can now be achieved in 16% of patients with initially unresectable CLM, resected after downsizing chemotherapy. Therefore, the importance of CLM tumor response evaluation following chemotherapy has gradually increased (4) .
Therefore, an imaging test is necessary for the prognostic prediction of the response of hepatic metastasis to chemotherapy, in order to identify patients likely to respond poorly to a chemotherapeutic regimen. This may allow for changes to the treatment plan that avoid unnecessary drug toxicity and maximize chances of tumor regression.
Accurate evaluation of therapeutic responses to treatment could have considerable clinical benefit for patients who receive chemotherapy. Although target therapies are increasingly being used in patients with advanced cancer, it is clear that standard tumor response evaluation methods are of limited value for assessment of treatment modality efficacy. Because of their varying mechanisms of action, it follows that the response patterns with target therapies differ from those seen with cytotoxic treatment. According to a previous renal cell carcinoma trial, the Response Evaluation Criteria in Solid Tumors (RECIST) often underestimate the effect of targeted therapy, because necrosis or hemorrhage frequently occur without any change in size (5, 6) . In addition, it remains to be determined whether these one-dimensional criteria can sufficiently reflect treatment responses to combined targeted biological therapy, although RECIST criteria is widely used for the evaluation of responses to cytotoxic chemotherapy (7, 8) .
In previous studies, volumetric measurement has been preferred over RECIST criteria, to predict tumor progression (9, 10) . Volumetric analysis has the ability to account for three dimensions, as opposed to RECIST criteria, in which only a single axial dimension is analyzed.
Therefore, we hypothesized that volumetric analysis would be superior to RECIST criteria, for the evaluation of tumor response after targeted therapy. The aim of this study was to compare RECIST and volumetric measurements of tumor response and outcome in CLM treated with a targeted agent plus folinic acid, fluorouracil, and irinotecan (FOLFIRI).
MATERIALS AND METHODS

PATIENTS POPULATION
This retrospective, single institutional analysis was approved by our Institutional Review Board (GAIRB2017-354), and requirement for informed consent was waived. CRC patients with unresectable liver metastases, treated with targeted therapy as first-line chemotherapy, were identified between January 2014 and January 2016, we identified CRC patients. Study inclusion was based on the unresectability of liver metastases, evaluated by a local multidisciplinary team. Patients that met ≥ 1 of the following criteria were included: 1) impossible 
CT EXAMINATIONS
All patients underwent contrast-enhanced multi-detector CT scans, including triple, double (arterial and portal venous phases), and single-phase CT (portal venous phase), before and after chemotherapy, with 64-or 128-detector CT scanners (Somatom Definition 64, and Somatom Definition Flash, Siemens Medical Solutions, Erlangen, Germany). Arterial and portal venous phase images were obtained with delays of 18 and 50 seconds, respectively, due to the 100 Hounsfield unit (HU) enhancement of the descending aorta using a bolus tracking method. Scans were obtained with a fixed delay of three minutes following the start of the 
IMAGE ANALYSIS
Images were interpreted by two radiologists, (S.J.C. has 7 years of abdominal imaging experience, and C.R.S. has 4 years of training as a radiology resident), blinded to patient demographics, clinical information, and official CT report. Tumor diameter and volume of the liver metastases, were s measured from the baseline and first follow-up CT scans. Baseline CT scans were performed within 4 weeks prior to the start of treatment, and the first follow-up CT scan was performed after three cycles of chemotherapy. For each patient, two target lesions were selected for analysis (11) . Target lesions were determined as the largest, most reproducible, and dominant lesions, treated during chemotherapy. Tumor volumes were mea- 
RESPONSE ASSESSMENT
Overall treatment response was classified as complete response (CR), partial response (PR), progressive disease (PD), or stable disease (SD), according to both RECIST 1.1, and volumetric criteria. Treatment response calculated using the mean of two times the tumor diameter, was used for classification according to RECIST 
STATISTICAL ANALYSIS
Categorical data, presented as percentages, frequencies, and differences in proportion, At the baseline, the tumor volume was 2.7 cm 3 in the left lobe of the liver (arrow at C). After the treatment, the tumor volume slightly decreased and was 2.0 cm 3 (26% reduction in the total volume of the target lesion arrow at D). E, F. Example of the progressing group based on the volumetric criteria. CLM in a 47-year-old woman is shown, with the baseline and first follow-up CT images obtained in the portal venous phase in a patient with CLM treated with bevacizumab plus FOLFIRI. At the baseline, the tumor volume was 22 cm 3 in the right posterior section of the liver (arrow at E). After the treatment, the tumor volume increased and was 47 cm 3 (113% increase in the total volume of the target lesion; arrow at F). CLM = colorectal liver metastasis, FOLFIRI = folinic acid, fluorouracil, and irinotecan, ROI = region of interest were compared using unpaired student's t-tests. Cumulative survival analysis was performed using the Kaplan-Meier (KM) method, and differences in survival between groups were assessed using the log-rank test. Potential prognostic factors of survival were evaluated using the Cox proportional hazard model. Univariate analyses were performed to identify significant predictors of survival. Characteristics determined to be statistically significant (p < 0.1) by the univariate analysis were used as input variables in a multivariate logistic regression analysis. Statistical analyses were performed using SPSS/PC version 20.0 (IBM Corp., Armonk, NY, USA). p-value < 0.05, were considered statistically significant.
RESULTS
PATIENTS DEMOGRAPHICS
CRC demographics and liver mass results are shown in Table 1 . Of the 43 patients, 27 (63%) had colon cancer, and 16 (37%) had rectal cancer. Of these, 34 (79%) had more than three liver metastases and a total of 61 target lesions were examined. Baseline liver metastases were greater than 3 cm in diameter in 30 patients (70%), with an average volume of 56.7 cm 3 (range, 1.1-328 cm 3 ; standard deviation, 81.9). In addition to FOLFIRI, 31 patients (72%) received bevacizumab, and 12 (28%) received cetuximab. Table 2 summarizes response assessment results based on RECIST and volumetric criteria. In patients classified as non-progressing or progressing by RECIST, the median overall survival was 19.5 months (95% CI, 422.56-747.44), and 12.4 months (95% CI, 305.79-440.21), respectively (p = 0.096, Log-rank test).
COMPARISON OF RECIST VS. VOLUMETRIC CRITERIA
In patients classified as non-progressing or progressing by volumetric criteria, the median overall survival was 21 months (95% CI, 491.25-768.75), and 11 months (95% CI, 0-949.42), re- The median overall survival in the non-progressing group (21 months) based on the volumetric criteria was longer than that in the progressing group (11 months; p = 0.001; Log-rank test). There were no statistically significant differences in the overall survival between the progressing and non-progressing groups according to the RECIST 1.1 or between the responder and non-responder groups according to the volumetric criteria and RECIST 1.1.
RECIST = Response Evaluation Criteria in Solid Tumors
spectively (p = 0.001, Log-rank test) (Fig. 2) .
UNIVARIATE AND MULTIVARIATE ANALYSIS
Univariate analyses based on a Cox proportional hazard model were performed to identify significant predictors of overall survival (Table 3 ). We found that age [Hazard ratios (HR):
1.038, p = 0.037], CA 19-9 (HR: 1.917, p = 0.055), and volumetric response (HR: 3.460, p = 0.002), were significant factors affecting overall survival (p-values less than 0.1). Multivariate analyses found that CA 19-9 (HR: 2.023, p = 0.042), and volumetric response (HR: 3.467, p = 0.003), were significant factors affecting overall survival (Table 4 ).
DISCUSSION
Our study demonstrates that volumetric measurement may have the potential to predict overall survival in patients with unresectable CLM treated with target therapy. Accurate and early detection of treatment response of liver metastases is important for optimal intervention planning (12) . Early, reliable prognostic information may help physicians to develop proper treatment plans for individual patients, and allow for more timely attempts of alternative therapies for treatment-resistant tumors.
RECIST criteria is easy to use, allows for rapid classification, and is highly reproducible and therefore, is widely used in clinical trials and clinical practice (13) . However, increases in the sophistication of imaging instrumentation has led to the development of markedly diverse and complex oncologic therapies (14) . For example, volumetric image assessment allows precise three-dimensional measurement of tissue volumes (15) . In this study, the nonprogressing group showed longer overall survival than the progressing group based on volumetric criteria, while the RECIST criteria was not significantly different between them.
Three patients were additionally assessed as PD according to volumetric criteria and SD according to RECIST criteria. We hypothesized that volumetric evaluation allowed precise mea-Volumetric Response Evaluation of Colorectal Liver Metastases surement of the geometric tumor and reflected smaller changes more than the traditional criteria (16, 17) . In addition, there was no significant difference between the responder and non-responder groups according to the volumetric and RECIST criteria. Molecular targeted therapy is often associated with potential intratumoral hemorrhage and peritumoral edema;
this is attributed to increasing tumor size despite good clinical response. Because of the apparent increase in lesion size, SD may often be misinterpreted as PD (18, 19) .
The National Comprehensive Cancer Network and European Society for Medical Oncology guidelines (20, 21) suggest an active combination regimen doublet chemotherapy plus a targeted agent (e.g. bevacizumab or cetuximab for KRAS wild-type tumors). Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), prevents VEGF from binding to its functional receptor, leading to the inhibition of tumor vessel growth, neovascularization, and decreased permeability in the surviving vasculature. Cetuximab, a monoclonal antibody against epidermal growth factor receptor, inhibits downstream signaling pathways, leading to the inhibition of cell proliferation and angiogenesis (22) . Targeted therapies have different mechanisms of action than cytotoxic chemotherapy. Some agents induce apoptosis, whereas other agents stop progression. Due to these differences in the mechanisms of action, tumors treated with targeted therapies may not demonstrate radiographic findings similar to that of tumors treated with conventional cytotoxic therapies (23) .
Therefore, traditional diameter-based criteria can lead to improper classification of treatment response for tumors treated with targeted therapies.
Our results further support the necessity for revised RECIST criteria that includes the use of volume measurements, in the response assessment of metastatic tumor burden in the liver after treatment with target agents. Similarly, another group has reported the need for revised RECIST criteria, adopting the concept of volumetry superiority over unidimensional measurements (24) . Conversely, volumetric measurements are cumbersome and time consuming, and thus, are unlikely to be widely adopted in clinical practice. However, recent technological advancement in medical imaging software has promised to provide solutions for rapid, easy, and accurate volume measurements (25, 26) .
Response evaluation with RECIST criteria is limited by the use of a unidimensional measurement as a surrogate marker for three-dimensional growing tumors. Conventional oneor two-dimension tumor measurements are made based on the assumption that lesion diameter is correlated to lesion volume. This assumption is due to the inaccurate belief that tumors grow and shrink in a spherical pattern. Volumetric measurements may more accurately reflect actual tumor size and shape compared to conventional measurements (8) .
Advances in CT technology allow for the acquisition of isotropic data with accurate and reproducible tumor volumetric data (15) . Semi-automated segmentation techniques use software algorithms to measure tumor volume based on ROI outlines drawn by the reader. Recently, the feasibility of volumetric tumor measurement as well as semiautomatic quantification of viable tumor (enhancing portion), has been shown for hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (27) . Volumetric quantification of HCC necrosis has been shown to be more reproducible than quantification using EASL criteria (28) . As RECIST is primarily based on one-dimensional measurements of the longest diameters of the tumors in a transverse image, it is often difficult for radiologists to determine the longest diameters in cases in which the target lesions split into smaller tumor, or merge to form a conglomerate mass after intervention (9, 29) . A previous study used RECIST to assess responses to imatinib in gastrointestinal stromal tumors, and found that the time to tumor progression did not differ between good and poor responders, suggesting that RECIST is not effective for this assessment. Similarly, Chun et al. (30) demonstrated that response assessment based on RECIST criteria was not correlated to overall survival in patients with CLM treated with target agents.
Instead, interest and acceptance of volumetric evaluation as an alternative assessment method has increased (31, 32) . An important theoretical advantage of volumetric evaluation is that it offers more accurate measurement and reflection of tumor burden, with less inter-observer variability, and is superior to measurements of the longest diameters from up to five target lesions per organ (15) . Previous studies have also reported that pretreatment tumor volume of HCC is a potential predictor of posttransplant recurrence (33, 34) .
Our study has several limitations. First, our study had a small number of patients. A larger series is needed to clinically validate our results. Second, our analysis was a retrospective assessment of dominant index lesions and non-target lesions were not included. However, several studies established that prognostic use of the dominant lesion, is sufficient to predict outcome after treatment (30, 35, 36) . This access is based on the assumption that the longest tumors can reflect tumor burden and, represent the most aggressive condition of the cancer.
Third, we enrolled CLM patients treated with different target agents (bevacizumab and cetuximab). However, both bevacizumab and cetuximab are now routinely used molecular target agents in metastatic CRC. Thus, this study could reflect real-time clinical practice.
In conclusion, volumetric assessment of liver metastases may become the preferred method to detect tumor progression, and predict overall survival for patients with unresectable liver metastases from CRC treated with a targeted agent.
